TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02778386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Methanocarbathymidine
Description: Patients will receive 200 mg, 400 mg, 800 mg or 1200 mg of N-Methanocarbathymidine administered orally on day 1 after subject's full screen for each cohort. Each dose will be completely evaluated for safety and pharmacokinetics. The doses of each cohort will be given after complete evaluation of the preceding cohort for any sign of toxicity. In the absence of no observed toxicity, the next cohort will be started in the normal subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Methanocarbathymidine
Description: Patients will receive 200 mg, 400 mg, 800 mg or 1200 mg of N-Methanocarbathymidine administered orally on day 1 after subject's full screen for each cohort. Each dose will be completely evaluated for safety and pharmacokinetics. The doses of each cohort will be given after complete evaluation of the preceding cohort for any sign of toxicity. In the absence of no observed toxicity, the next cohort will be started in the normal subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Methanocarbathymidine
Description: Patients will receive 200 mg, 400 mg, 800 mg or 1200 mg of N-Methanocarbathymidine administered orally on day 1 after subject's full screen for each cohort. Each dose will be completely evaluated for safety and pharmacokinetics. The doses of each cohort will be given after complete evaluation of the preceding cohort for any sign of toxicity. In the absence of no observed toxicity, the next cohort will be started in the normal subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Methanocarbathymidine
Description: Patients will receive 200 mg, 400 mg, 800 mg or 1200 mg of N-Methanocarbathymidine administered orally on day 1 after subject's full screen for each cohort. Each dose will be completely evaluated for safety and pharmacokinetics. The doses of each cohort will be given after complete evaluation of the preceding cohort for any sign of toxicity. In the absence of no observed toxicity, the next cohort will be started in the normal subjects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Capsule
Description: Two patients in Cohort 3 \& 4 will receive placebo capsules which is mannitol filled into size 0 capsules.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Capsule
Description: Two patients in Cohort 3 \& 4 will receive placebo capsules which is mannitol filled into size 0 capsules.
Study: NCT01652066

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixture of probiotics
Description: effect of the consumption a mixture of probiotics ( dietary supplement tablet - dosage at least 10x7 cfu/g) during 7 weeks , once a day , healthy volonteers ) on the antigen specific antibody respense

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mixture of probitiocs
Description: effect of the consumption a mixture of probiotics ( dietary supplement tablet - dosage at least 10x7 cfu/g) during 7 weeks , once a day , healthy volonteers ) on the antigen specific antibody respense
Study: NCT01375582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B & L Soothe Lubricant Eye Drops
Description: Eye Drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposic EDO
Description: Eye Drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OcuFresh Eye Wash
Description: Saline drop
Study: NCT00043186

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab for subcutaneous injection
Study: NCT03080584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: 12 weeks of acupuncture comprising basic acupuncture, ear acupuncture and Moving cups. On top of the basic acupuncture, additional locations can be added.
Study: NCT04401280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BiominF
Description: in office application of bioactive glass followed by self administered application by the patient until a point of white spot remineralization is reached

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novamin
Description: in office application of bioactive glass followed by self administered application by the patient until a point of white spot remineralization is reached

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPP-ACP
Description: applied in accordance with the manufacturer's specifications
Study: NCT02865200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling Application
Description: Dry needling was performed on active and/or latent TPs at Gluteus Medius, Quadratus Lumborum, Multifidus, Erector Spinae muscles of the subjects in the study groups without applying any local anesthetic substance. The needles were applied with a 90º angle for Multifidus, Quadratus Lumborum and Gluteus Medius muscles; while they were applied with a 45º angle for Erector Spinae muscles. Thin stainless steel needles of 0.25x0.40 mm and 0.30x0.60 mm were applied in infiltration form on the TP through many points in conformity with the injection technique.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classic Physiotherapy Program
Description: Hot-pack was applied for 20 minutes. Burst TENS was applied on the lumbar regions of the cases of the control group paravertebrally with 4-electrode reusable silicone rubber. The dimensions of electrode is 5x5cm. Pulse width was set for 100 µsn, pulse frequency was set for 2 Hz, cycle time is set for 0.5 seconds and the amplitude was increased until visible muscle contraction was reached. If the muscle contraction is lost during the session, the amplitude was increased again.~Ultrasound was paravertebrally applied to the lower back regions of the subjects. The treatment was applied with 1 MHz frequency, 1.5 W/cm2 power, for 6 minutes a day, for 10 sessions in total with direct contact with the patient's skin.
Study: NCT03718754

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: En-Bloc TURB
Description: En-bloc resection will be performed at each center based on local clinical practice and available instruments. Laser resection, hydrodissection with HybridKnife® or electric resection are allowed. All procedures, including cTURB, must be performed with an imaging enhancing technique (PDD / NBI at surgeon's discretion). After resection, a single intravesical instillation of 40mg Mitomycin-C will be performed if clinically feasible.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional TURB
Description: En-bloc resection will be performed at each center based on local clinical practice and available instruments. After resection, a single intravesical instillation of 40mg Mitomycin-C will be performed if clinically feasible.
Study: NCT02929966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: palliative care program
Description: The program includes psychological support, spiritual care and respiratory therapist support

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard respiratory care
Description: the usual standard pharmacological care plus oxygen therapy
Study: NCT03563664

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre-treatment endometrial biopsy
Description: Timed suction endometrial biopsy was obtained from participants via Wallach Endocell® 908014A endometrial cell sampler timed during the implantation window of the pretreatment cycle; followed by immunohistochemical staining using immunoperoxidase staining incorporating avidin-biotin complex (ABC) method.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol
Description: Participants were treated with danazol (Danol® 200mg capsules, Sanofi, Guildford, UK) in daily dosage of 400 mg for 12 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-treatment endometrial biopsy
Description: Post-treatment suction endometrial biopsy was obtained during the implantation window following the first ovulation after danazol treatment, timed, processed and stained as described previously.
Study: NCT04965103

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCR
Description: Superior Capsule reconstruction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bridging
Description: Tendon repair with graft interposition
Study: NCT03960424

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Outpatient Management
Description: Patients receiving comprehensive outpatient management experience typical care received in the outpatient setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Telemonitoring
Description: Diabetes Telehealth Management (DTM), based on the 2018 ADA Standards for T2D, uses smart devices to share information between patients, caregivers, and clinicians.
Study: NCT01935245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini extracorporeal circulation
Description: Minimal-ECC versus conventional ECC circuits minimise foreign surface-blood interaction and are heparinized from tip to tip. The tubing length has been shortened to decrease crystalloid prime. Cardiotomy suction is minimised, which leads to less fibrinolysis. An active air-removal device is added to the closed circuit.~The use of minimal ECC has already shown a significant reduction of the systemic inflammatory reaction and less peroperative transfusion of blood products.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional extracorporeal circulation
Study: NCT02890849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid biopsy
Study: NCT02464865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine 1
Description: If severe symptoms and signs of thiamine deficiency are present, thiamine is prescribed.~Intervention 1 : severe symptom (heart failure, convulsion, or coma) : 50 mg thiamin administered very slowly intravenously, followed by a daily intramuscular dose of 10 mg for a week, and finally followed by 3-5 mg of thiamine per day orally for at least 6 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Non-thiamine
Description: no symptoms and signs of thiamine deficiency

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine 2
Description: If symptoms and signs of thiamine deficiency are present, thiamine is prescribed.~If mild symptom : a daily oral dose of 10 mg thiamin during the first week, followed by 3-5 mg of thiamin per day orally for at least 6 weeks
Study: NCT01025648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E004 (epinephrine inhalation aerosol), 90 mcg/actuation
Description: E004 (epinephrine inhalation aerosol), 90 mcg/actuation, 2 actuations, single dose crossover, 1 -14 day washout period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E004 Placebo
Description: E004 Placebo, 0 mcg epinephrine inhalation aerosol, 2 actuations, 1 -14 day washout period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E004 (epinephrine inhalation aerosol), 125 mcg
Description: E004 (epinephrine inhalation aerosol), 125 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 day washout period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E004 (epinephrine inhalation aerosol), 220 mcg
Description: E004 (epinephrine inhalation aerosol), 220 mcg - 220 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine inhalation aerosol, CFC propelled
Description: epinephrine inhalation aerosol, 220 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 day washout period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E004 (epinephrine inhalation aerosol), 160 mcg
Description: E004 (epinephrine inhalation aerosol), 160 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period
Study: NCT01606202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW-1000-02
Description: Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml):cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.7 mg and CBD 2.5 mg). The maximum permitted dose of study medication was eight actuations in any three-hour period, and 48 actuations in any 24 hour period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three-hour period, and 48 actuations in any 24 hour period.
Study: NCT01526876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clevidipine butyrate
Description: intravenous infusion dose range 1.0 mg/hr - 32 mg/hr titrate to blood pressure effect duration of infusion: 6 hours
Study: NCT02363985

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Mega-dose of vitamin A supplement
Description: vitamin A supplementation normally given every six months for under five children in Ethiopia. In addition, there is also dietary intervention like orange flash sweet potato and promotion of other vitamin A rich foods to tackle vitamin A deficiency in Ethiopia.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Mega-dose of vitamin A supplement
Description: vitamin A supplementation normally given every six months for under five children in Ethiopia. In addition, there is also dietary intervention like orange flash sweet potato and promotion of other vitamin A rich foods to tackle vitamin A deficiency in Ethiopia.
Study: NCT04262804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Margetuximab
Description: Margetuximab IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chosen Chemotherapy (Capecitabine)
Description: Capecitabine tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chosen Chemotherapy (Capecitabine)
Description: Capecitabine tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chosen Chemotherapy (Vinorelbine )
Description: Vinorelbine IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chosen Chemotherapy (Vinorelbine )
Description: Vinorelbine IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chosen Chemotherapy (Gemcitabine )
Description: Gemcitabine IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chosen Chemotherapy (Gemcitabine )
Description: Gemcitabine IV
Study: NCT03946228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: The intervention will be delivered by trained research staff who are exercise physiologists or behavioral lifestyle counselors. This target reflects a recent expert statement concluding that desk-based workers should reduce workday sedentary behavior by 2-4 hr (by increasing standing and movement). The approach will combine: behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts. The initial in-person session will occur at the participant's office location. During months 2 and 3, one-on-one in-person meetings will occur at the research lab. Telephone intervention contacts will occur in the 3rd week of months 1-3.
Study: NCT06192498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses
Description: Virtual Reality(VR) Glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses before starting the application and it continued until the end of the Blood Draw procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kaleidoscope
Description: Kaleidoscope were introduced to the children pre-procedure. The children were made to watch Kaleidoscope before starting the application and it continued until the end of the Blood Draw procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distraction Cards
Description: Distraction Cards were introduced to the children pre-procedure. The children were made to apply Distraction Cards before starting the application and it continued until the end of the Blood Draw procedure.
Study: NCT01210352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxymorphone HCl
Description: Comparison of different dosages of drug, 0.05mg/kg, 0.10mg/kg, 0.15mg/kg or 0.20mg/kg oral liquid oxymorphone
Study: NCT00913224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voltaren 50 mg Tablets (Geigy Pharmaceuticals)
Study: NCT01137461

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ultrasound-guided embryo transfer
Description: Embryo transfer in oocyte recipients

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ultrasound-guided embryo transfer
Description: Embryo transfer in oocyte recipients
Study: NCT01238094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: simvastatin 40 mg qd daily until disease progression
Study: NCT03278405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
Study: NCT02488590

Intervention type: DRUG
Intervention: LABA + LAMA
Description: An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.

Intervention type: DRUG
Intervention: ICS
Description: An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.

Intervention type: DRUG
Intervention: LABA + LAMA + ICS
Description: An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.

Intervention type: DRUG
Intervention: LABA + ICS
Description: An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.

Intervention type: DRUG
Intervention: other
Description: An open label therapy or no therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
Study: NCT01836809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nesiritide
Description: nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesiritide
Description: nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
Study: NCT04698421

Intervention type: BIOLOGICAL
Intervention: Blood collection on admission and longitudinally
Description: Biological samples will be collected in the normal diagnosis and follow-up process. Only blood will be taken in larger quantity (8 tubes of 7mL).
Study: NCT03174678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 1µg/kg dexmedetomidine oral
Study: NCT00043186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab for subcutaneous injection
Study: NCT03174678

Intervention type: OTHER
Group type: OTHER
Intervention: apple juice
Description: apple juice
Study: NCT02838589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Byetta
Description: Single dose of subcutaneous injection of 5 μg exenatide (Byetta).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: Single dose of subcutaneous injection of 20 μL isotonic saline (placebo).
Study: NCT03632538

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide)
Description: Drawing of patients blood for measurement of biomarkers for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours).

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide)
Description: Drawing of patients blood for measurement of biomarkers for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours).
Study: NCT03888183

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: salt solution without 0.15% HA
Description: received AIM Artificial Tears (4 to 8 times per day) with 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: preservative-free 0.15% HA
Description: received Per-Young Eye Drops (4 to 8 times per day) with 12 weeks
Study: NCT00556738

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Continuous Positive Airway Pressure ventilation
Description: Nasal Continuous Positive Airway Pressure ventilation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrapulmonary Percussive Ventilation
Description: Intrapulmonary Percussive Ventilation